Department of Neurology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Curr Opin Rheumatol. 2011 Nov;23(6):612-9. doi: 10.1097/BOR.0b013e32834b324b.
Necrotizing autoimmune myopathy (NAM) is a relatively newly recognized subgroup of idiopathic inflammatory myopathies, which despite diverse causes, have the common histopathological features of myocyte necrosis without significant inflammation. Patients present with a subacute severe symmetrical proximal myopathy, associated with a markedly elevated creatine kinase level. These are most likely immune-mediated, as they respond to immunotherapy. The review aims to define this heterogeneous entity and summarize the salient clinical, laboratory, and muscle biopsy findings, in order to facilitate the diagnosis and treatment of this condition.
Statin-associated NAM has been linked with an antibody against the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) protein, which is up-regulated in regenerating fibres. This finding suggests that NAM is an antibody-mediated disease, and may explain the continuing progression of disease despite cessation of the statin. In addition it may provide a useful diagnostic test in the future, to help differentiate immune from nonimmune statin myopathies.
It is important to recognize and distinguish NAM from other causes of myocyte necrosis, because it has the potential of being amenable to treatment.
坏死性自身免疫性肌病(NAM)是一种相对较新认识的特发性炎性肌病亚组,尽管病因不同,但都具有肌细胞坏死而无明显炎症的共同组织病理学特征。患者表现为亚急性严重对称性近端肌无力,伴有肌酸激酶水平显著升高。这些很可能是免疫介导的,因为它们对免疫治疗有反应。本综述旨在定义这一异质实体,并总结其显著的临床、实验室和肌肉活检表现,以便于诊断和治疗。
与他汀类药物相关的 NAM 与一种针对 3-羟基-3-甲基戊二酰辅酶 A 还原酶(HMGCR)蛋白的抗体有关,该蛋白在再生纤维中上调。这一发现表明 NAM 是一种抗体介导的疾病,这可能解释了尽管停止使用他汀类药物,疾病仍在继续进展。此外,它可能在未来提供一种有用的诊断测试,以帮助区分免疫性和非免疫性他汀类肌病。
识别和区分 NAM 与其他肌细胞坏死的原因很重要,因为它有可能进行治疗。